TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Should You Buy Viking Therapeutics Before Nov. 5?

The Motley Fool Logo The Motley Fool • •By Adria Cimino
Should You Buy Viking Therapeutics Before Nov. 5?

Viking Therapeutics is developing a promising weight loss drug (VK2735) in phase 3 trials, targeting the rapidly growing obesity drug market. The company has shown potential with clinical trial results indicating up to 13.1% average weight loss, and is presenting research at upcoming medical conferences.

Insights
VKTX   positive

Strong clinical trial results, promising drug candidate in a growing market, potential to compete with major pharmaceutical companies